

AMENDMENTS TO THE CLAIMS

Claims 1-14 (canceled).

Claim 15 (currently amended): A method of diagnosing ~~DKK1-associated~~ lytic bone disease treatable by decreasing DKK-1 expression in an individual, comprising:

measuring the expression level of the human homologue of Dickkopf-1 (DKK-1) protein in said individual, wherein an increased expression of said protein compared to that in a healthy individual indicates that said individual has ~~DKK1-associated~~ a lytic bone disease treatable by decreasing DKK-1 expression therein.

Claims 16-17 (canceled).

Claim 18 (previously presented): The method of claim 15, wherein said expression level is measured by enzyme-linked immunosorbent assay, immunohistochemistry or flow cytometry.

Claims 19 (previously presented): The method of claim 15, wherein said individual has multiple myeloma.

Claims 20-38 (canceled).

Claim 39 (new): A method of diagnosing DKK1-associated lytic bone disease in an individual having multiple myeloma, comprising:

measuring the expression level of the human homologue of Dickkopf-1 (DKK-1) protein in said individual, wherein an increased expression of said protein compared to that in a healthy individual indicates that said individual has DKK1-associated lytic bone disease.

Claim 40 (new): The method of claim 39, wherein said expression level is measured by enzyme-linked immunosorbent assay, immunohistochemistry or flow cytometry.